Normal view MARC view ISBD view

Second-Generation Drug-Eluting Resorbable Magnesium Scaffold: Review of the Clinical Evidence. [Review]

MedStar author(s):

Citation: Cardiovascular Revascularization Medicine. 21(1):127-136, 2020 01.PMID: 31662277Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Absorbable Implants | *Cardiovascular Agents/ad [Administration & Dosage] | *Coated Materials, Biocompatible | *Coronary Artery Disease/th [Therapy] | *Magnesium | *Percutaneous Coronary Intervention/mo [Mortality] | Animals | Cardiovascular Agents/ae [Adverse Effects] | Coronary Artery Disease/dg [Diagnostic Imaging] | Humans | Percutaneous Coronary Intervention/ae [Adverse Effects] | Prosthesis Design | Risk Factors | Treatment OutcomeYear: 2020 Local holdings: Available in print through MWHC library: 2002 - presentISSN:

1878-0938

Name of journal: Cardiovascular revascularization medicine : including molecular interventionsAbstract: Since October 8, 2013, the second-generation drug-eluting resorbable magnesium scaffold (RMS) has been used to treat coronary lesions. At present, the second-generation drug-eluting RMS is clinically available in Europe, some South American countries, and some Asian and African countries. Furthermore, patients are currently being enrolled in ongoing post-marketing trials. This device has the potential to be an alternative to drug-eluting stents in the future, but there is not yet sufficient evidence. This review provides the latest available evidence, comparison with other bioresorbable scaffolds, future perspectives, and discussion of clinical case reports with second-generation drug-eluting RMS. SUMMARY: Favorable outcomes have been reported after second-generation drug-eluting RMS implantation. More long-term clinical outcomes for this novel device are still required in the future. Copyright (c) 2019 Elsevier Inc. All rights reserved.All authors: Garcia-Garcia HM, Hideo-Kajita A, Ozaki Y, Shlofmitz E, Waksman ROriginally published: Cardiovascular Revascularization Medicine. 2019 Oct 22Fiscal year: FY2020Digital Object Identifier:

https://dx.doi.org/10.1016/j.carrev.2019.10.012

Date added to catalog: 2019-11-19

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	31662277	Available		31662277

Available in print through MWHC library: 2002 - present

Since October 8, 2013, the second-generation drug-eluting resorbable magnesium scaffold (RMS) has been used to treat coronary lesions. At present, the second-generation drug-eluting RMS is clinically available in Europe, some South American countries, and some Asian and African countries. Furthermore, patients are currently being enrolled in ongoing post-marketing trials. This device has the potential to be an alternative to drug-eluting stents in the future, but there is not yet sufficient evidence. This review provides the latest available evidence, comparison with other bioresorbable scaffolds, future perspectives, and discussion of clinical case reports with second-generation drug-eluting RMS. SUMMARY: Favorable outcomes have been reported after second-generation drug-eluting RMS implantation. More long-term clinical outcomes for this novel device are still required in the future. Copyright (c) 2019 Elsevier Inc. All rights reserved.

English